- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05365659
IKS03 u pacjentów z zaawansowanymi chłoniakami nieziarniczymi z komórek B
Faza 1 kohortowej próby zwiększania i rozszerzania dawki w celu określenia bezpieczeństwa, tolerancji, maksymalnej tolerowanej dawki i wstępnej aktywności przeciwnowotworowej IKS03 u pacjentów z zaawansowanym chłoniakiem nieziarniczym (NHL) z komórek B
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The study will consist of 2 parts: dose-escalation (Part I) and dose-expansion (Part II). The dose-escalation part (Part I) of the study is to evaluate the safety and tolerability of increasing dose levels of IKS03 to establish a recommended Phase 2 dose (RP2D); and the dose-expansion part (Part II) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of IKS03 at the RP2D.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: David Browning
- Numer telefonu: 615-975-7776
- E-mail: david.browning@iksuda.com
Lokalizacje studiów
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- Rekrutacyjny
- Westmead Hospital
-
Główny śledczy:
- Amanda Johnston, MD
-
-
South Australia
-
Adelaide, South Australia, Australia
- Rekrutacyjny
- Royal Adelaide Hospital
-
Kontakt:
- Pratyush Giri, MBBS
-
Główny śledczy:
- Pratyush Giri, MBBS
-
-
Tasmania
-
Hobart, Tasmania, Australia, 7000
- Rekrutacyjny
- Royal Hobart Hospital
-
Główny śledczy:
- Rosemary Harrup, MD
-
-
Western Australia
-
Perth, Western Australia, Australia
- Rekrutacyjny
- Linear Clinical Research
-
Kontakt:
- Katharine Lewis, MD
-
Główny śledczy:
- Katharine Lewis, MD
-
-
-
-
-
Badalona, Hiszpania
- Rekrutacyjny
- Institut Catala D'Oncologia
-
Kontakt:
- Mireia Franch-Sarto, M.D.
-
Główny śledczy:
- Mireia Franch-Sarto, M.D.
-
Madrid, Hiszpania
- Rekrutacyjny
- Hospital Universitario Quironsalud Madrid
-
Kontakt:
- Maria del Carmen Martinez-Chamorro, M.D.
-
Główny śledczy:
- Maria del Carmen Martinez-Chamorro, M.D.
-
Salamanca, Hiszpania
- Rekrutacyjny
- Hospital Clinico Universitario de Salamanca
-
Kontakt:
- Alejandro Martin Garcia-Sancho, M.D.
-
Główny śledczy:
- Alejandro Martin Garcia-Sancho, M.D.
-
-
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Rekrutacyjny
- Jewish General Hospital
-
Główny śledczy:
- Sarit Assouline, MD
-
Kontakt:
- Sarit Assouline, MD
-
-
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21201
- Wycofane
- University of Maryland Baltimore
-
-
-
-
-
Candiolo, Włochy
- Rekrutacyjny
- Istituto Nazionale Oncologico Candiolo
-
Kontakt:
- Umberto Vitolo, M.D.
-
Główny śledczy:
- Umberto Vitolo, M.D.
-
Milan, Włochy
- Rekrutacyjny
- Istituto Europeo di Oncologia
-
Kontakt:
- Enrico Derenzini, M.D.
-
Główny śledczy:
- Enrico Derenzini, M.D.
-
Milan, Włochy
- Rekrutacyjny
- Istituto Europeo Clinico Humanitas
-
Kontakt:
- Carmelo Carlo-Stella, M.D.
-
Główny śledczy:
- Carmelo Carlo-Stella, M.D.
-
Milan, Włochy
- Rekrutacyjny
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele
-
Kontakt:
- Andres Jose Maria Ferreri, M.D.
-
Główny śledczy:
- Andres Jose Maria Ferreri, M.D.
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Males or females, ≥ 18 years of age
-
Part I: documented B cell NHL (any subtype except Burkitt lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia); previously confirmed CD19-positive if feasible
-
Part II: documented B cell NHL (subtypes to be determined); confirmed CD19-positive; possible expansion cohorts may include:
- Diffuse large B cell lymphoma (including germinal center B cell type, activated B cell type)
- Follicular lymphoma (including duodenal-type follicular lymphoma)
- Mantle cell lymphoma
- B cell lymphomas not specified
-
If B cell NHL subtype likely to have bone marrow involvement must be willing to undergo bone marrow biopsy in the event of an on-study complete response to confirm response
-
NHL that is relapsed, refractory to, or intolerant of existing therapy(ies) with known curative potential, or for which no standard therapy is available; must have received at least 2 prior lines of systemic therapy
-
Must be in need of systemic treatment and not require immediate cytoreductive therapy
-
Part I: measurable or non-measurable disease
-
Part II: measurable disease according to The Revised Criteria/Lugano Classification
-
Part I: screening tumor biopsy requested, but optional; Part 2: patient must agree to screening tumor biopsy
-
ECOG performance status 0 or 1
-
Women of childbearing potential and fertile men agreeing to use two effective methods of contraception (including a highly effective method of contraception); women beginning 2 weeks prior to the first dose, men beginning prior to the first dose, and both continuing until 8 months after the last dose of study drug; male patients must also agree to refrain from sperm donation during this period.
-
Ability to understand and give written informed consent
Exclusion Criteria:
-
Women who are pregnant or intending to become pregnant before, during, or within 8 months after the last dose of study drug; women who are breastfeeding
-
Patients documented to be CD19-negative
-
Central nervous system (CNS) lymphoma, leptomeningeal infiltration, or spinal cord compression not controlled by prior surgery or radiotherapy; symptoms suggesting CNS involvement
-
Part 2: History of another malignancy within 2 years, with the exception of:
- Treated, non-melanoma skin cancers
- Treated carcinoma in situ (e.g., breast, cervix)
- Controlled, superficial carcinoma of the urinary bladder
- T1a or b prostate carcinoma treated according to standard of care, with PSA within normal limits
- Papillary thyroid carcinoma Stage I treated surgically for cure
-
Any of the following hematologic abnormalities at baseline (transfusion allowed > 5 days previous):
- Hemoglobin < 8.0 g/dL
- Absolute neutrophil count < 1,000 per mm3
- Platelet count < 75,000 per mm3
-
Any of the following laboratory abnormalities at baseline:
- Total bilirubin > 1.5 × upper limit of normal (ULN); > 3 × ULN if with Gilbert's Syndrome
- AST or ALT > 3 × ULN; > 5 × ULN if due to hepatic involvement by tumor
- Estimated GFR ≤ 60 mL/min corrected for BSA
- Albuminuria defined as urine albumin to creatinine ratio < 30 mg/g or < 3 mg/mmol) by spot urine albumin
-
Any of the following coagulation parameter abnormalities at baseline unless on a stable dose of anticoagulant therapy for a prior thrombotic event:
- PT or INR > 1.5 × ULN; > 3× ULN if anticoagulated)
- PTT > 1.5 × ULN; > 3× ULN if anticoagulated
-
Any of the following laboratory abnormalities at baseline aimed at assessing renal function:
- Estimated glomerular filtration rate (eGFR) ≤ 60 mL/min, corrected for BSA.
- Albuminuria defined as urine albumin to creatinine ratio (UACR) ≥ 45 mg/g or ≥ 4.5 mg/mmol by spot urine albumin
-
Patients with:
- Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks unless adequately treated and stable
- Active uncontrolled bleeding or a known bleeding diathesis
-
Significant cardiovascular disease or condition, including:
- Congestive heart failure or angina pectoris requiring therapy
- Ventricular arrhythmia requiring therapy or other uncontrolled arrhythmia
- Severe conduction disturbance (e.g., 3rd degree heart block)
- QTc interval ≥ 480 milliseconds
- Left ventricular ejection fraction below the lower limit of normal or < 50% by MUGA scan or echocardiogram
- Class III or IV cardiovascular disease according to the New York Heart Association Functional Classification
- History of acute coronary syndromes (e.g., MI, unstable angina), coronary angioplasty, stenting, or bypass within 6 months
-
Significant liver disease, including:
- Non-infectious hepatitis
- Hepatic cirrhosis (Child-Pugh Class B and Class C)
-
Significant pulmonary disease or condition, including:
- Significant symptomatic COPD, as assessed by the Investigator
- History or any current evidence on imaging studies of interstitial lung disease, pulmonary fibrosis
- History of pulmonary inflammatory disease, pneumonitis, ARDS
- History of pneumonia within 1 month
-
Significant corneal disease or condition, including history of or current evidence of keratitis
-
Clinically significant CNS disease or condition including PML, epilepsy, vasculitis, or neurodegenerative disease. Also including TIA or stroke within 6 months
-
Known HIV infection or AIDS
-
Active hepatitis B virus or hepatitis C virus infection
-
Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks
-
Autoimmune disease or condition requiring systemic steroids or other immunosuppressive medications
-
Unresolved Grade > 1 AE associated with any prior antineoplastic therapy (except persistent Grade 2 alopecia, peripheral neuropathy, decreased hemoglobin, neutropenia, lymphopenia, hypomagnesemia, and/or endocrine end-organ failure being adequately managed by HRT)
-
Known or suspected hypersensitivity to any of the excipients of formulated study drug
-
Inadequate recovery from a surgical procedure, or a major surgical procedure within 4 weeks
-
Any other serious, life-threatening, or unstable preexisting medical condition, including significant organ system dysfunction, or clinically significant laboratory abnormality(ies)
-
A psychiatric disorder or altered mental status that would preclude understanding of the informed consent process
Drugs and Other Treatments to be Excluded:
-
Receipt of:
- Any CD19-targeted therapy within 4 weeks
- Any tumor vaccine within 6 weeks (must have progressed if previously received)
-
Prior autologous/allogeneic CAR-T therapy if known to be CD19-negative after
-
Any other antineoplastic agent for the primary malignancy without delayed toxicity within 3 weeks or 5 plasma half-lives, whichever is shortest (except nitrosoureas and mitomycin C within 6 weeks)
-
Any other investigational treatments within 3 weeks
-
Drugs known to impair renal function, including:
- NSAIDS within 3 days
- Aminoglycoside antibiotics, amphotericin B, etc. within 1 week
- Bisphosphonates within 1 month
-
Prior solid organ transplant
-
Allogeneic HSCT within 6 months, or:
- If receiving immunosuppression
- If with active evidence of GVHD
-
Autologous hematopoietic stem cell transplantation (HSCT) within 3 months
-
Radiotherapy:
- To target lesions within 4 weeks unless progression of the lesion has been documented
- To non-target lesions within 1 week
-
Live/live-attenuated vaccines against infectious diseases within 4 weeks
-
Immunosuppressive or systemic glucocorticoid therapy (> 10 mg prednisone daily or equivalent) within 2 weeks
-
Prophylactic use of hematopoietic growth factors within 1 week
-
Herbal therapies and supplements within 2 weeks
-
Strong inhibitors of cytochrome P450 within 2 weeks
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Dose Escalation Cohort (Part 1)
Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
Eksperymentalny: Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
Eksperymentalny: Dose Expansion: Follicular Cell Lymphoma Participants
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
Eksperymentalny: Dose Expansion: Mantle Cell Lymphoma Participants
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
Eksperymentalny: Dose Expansion: Other B cell lymphoma (B-NHL not otherwise specified [NOS])
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Recommended Phase 2 Dose (Part I)
Ramy czasowe: Up to 20 months
|
RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data |
Up to 20 months
|
|
Objective Response Rate (Part II)
Ramy czasowe: up to 42 months
|
Antineoplastic effects will be assessed by Criteria for Response Assessment: The Lugano Classification (Cheson 2014) |
up to 42 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Evaluation of the immunogenicity of IKS03 (Part I and II)
Ramy czasowe: Up to 42 months
|
Occurrence of ADA measured in serum at selected timepoints during the study |
Up to 42 months
|
|
Plasma Concentrations of IKS03 (Part I and II)
Ramy czasowe: Up to 42 months
|
Pharmacokinetic profile will be characterized by concentrations of IKS03 |
Up to 42 months
|
|
Determine recommended Phase 2 dose (RP2D) (Part II)
Ramy czasowe: Up to 42 months
|
Based on evidence of antitumor activity, acceptable tolerability, evidence of achieving target plasma concentration |
Up to 42 months
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Debra Wood, MD, Iksuda Therapeutics
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory
- Choroby układu odpornościowego
- Nowotwory według typu histologicznego
- Choroby limfatyczne
- Zaburzenia limfoproliferacyjne
- Zaburzenia immunoproliferacyjne
- Choroby hemowe i limfatyczne
- Chłoniak
- Chłoniak z komórek B
- Chłoniak, duże komórki B, rozlany
- Chłoniak nieziarniczy
- Chłoniak, Pęcherzykowy
- Chłoniak, Komórki Płaszcza
Inne numery identyfikacyjne badania
- IKS03-01
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .